Desvenlafaxine in Opioid-Dependent Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
DepressionOpioid DependenceMethadone Treatment
Interventions
DRUG

Desvenlafaxine

All subjects will receive 50 mg of the medication during week 1 and 2, then 50-100 mg (based on the psychiatrist judgment) for the following 6 weeks. Subjects who experience significant adverse reactions with the 100mg dose during weeks 2 to 4 could return to the lower dose of 50 mg if judged clinically appropriate by the study psychiatrist.

Trial Locations (1)

H2X0A9

Centre de recherche du Centre Hospitalier de l'Université de Montréal, Montreal

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER

NCT02200406 - Desvenlafaxine in Opioid-Dependent Patients | Biotech Hunter | Biotech Hunter